Abstract
Cytomegalovirus (CMV) is a leading cause of congenital infection worldwide and therefore is recognized as an important target for vaccine development. Data from natural infections and work done with animal models, including models of congenital infection, provide the rationale for their development. CMV vaccine evaluations were begun in the mid-1970’s with an attenuated live virus vaccine, Towne, but this vaccine has not consistently provided protection. Most recently, data from a trial with a subunit glycoprotein B (gB) vaccine administered with the adjuvant MF59 became available. This trial, conducted in post-partum women, demonstrated that the vaccine decreased CMV infections, increasing optimism that a protective CMV vaccine could be developed. Other approaches for CMV that have entered clinical trials include replicons, DNA vaccines, prime boost strategies, and chimeric live viruses. The replicon vaccine included gB and the T cell targets phosphoprotein (pp)65 and Immediate Early (IE)1 while the DNA vaccine was given with a new adjuvant and included gB and pp65. The optimal composition for a CMV vaccine remains to be defined but trials continue with the gB vaccine and others.
Keywords: Cytomegalovirus, congenital infection, replicons, DNA vaccines, chimeric, vectors, glycoprotein B (gB) vaccine, natural infections, vaccine evaluations, prime boost strategies, asymptomatic, immunosenescence, protective immune response, cytokines, neutralizing antibodies
Infectious Disorders - Drug Targets
Title: Vaccines for Cytomegalovirus
Volume: 11 Issue: 5
Author(s): D. I. Bernstein
Affiliation:
Keywords: Cytomegalovirus, congenital infection, replicons, DNA vaccines, chimeric, vectors, glycoprotein B (gB) vaccine, natural infections, vaccine evaluations, prime boost strategies, asymptomatic, immunosenescence, protective immune response, cytokines, neutralizing antibodies
Abstract: Cytomegalovirus (CMV) is a leading cause of congenital infection worldwide and therefore is recognized as an important target for vaccine development. Data from natural infections and work done with animal models, including models of congenital infection, provide the rationale for their development. CMV vaccine evaluations were begun in the mid-1970’s with an attenuated live virus vaccine, Towne, but this vaccine has not consistently provided protection. Most recently, data from a trial with a subunit glycoprotein B (gB) vaccine administered with the adjuvant MF59 became available. This trial, conducted in post-partum women, demonstrated that the vaccine decreased CMV infections, increasing optimism that a protective CMV vaccine could be developed. Other approaches for CMV that have entered clinical trials include replicons, DNA vaccines, prime boost strategies, and chimeric live viruses. The replicon vaccine included gB and the T cell targets phosphoprotein (pp)65 and Immediate Early (IE)1 while the DNA vaccine was given with a new adjuvant and included gB and pp65. The optimal composition for a CMV vaccine remains to be defined but trials continue with the gB vaccine and others.
Export Options
About this article
Cite this article as:
I. Bernstein D., Vaccines for Cytomegalovirus, Infectious Disorders - Drug Targets 2011; 11 (5) . https://dx.doi.org/10.2174/187152611797636695
DOI https://dx.doi.org/10.2174/187152611797636695 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: Chemo- and Bioinformatics in the Discovery of Antimalarial Drugs and Arthropod Repellents to Counter Vector Borne Diseases (VBDs))
Current Computer-Aided Drug Design Cytokine and Immune System Abnormalities in Fibromyalgia and Other Central Sensitivity Syndromes
Current Rheumatology Reviews The Effect of Pharmacotherapy for Attention Deficit Hyperactivity Disorder on Risk of Seizures in Pediatric Patients as Assessed in an Insurance Claims Database
Current Drug Safety The Yin and Yang of Antiviral Innate Immunity in Central Nervous System
Current Pharmaceutical Design Idiopathic Transverse Myelitis and Neuromyelitis Optica: Clinical Profiles,Pathophysiology and Therapeutic Choices
Current Neuropharmacology Commentary: (Research Highlights Inflammation, Demyelination and Neurodegeneration: Risky Buddies in Multiple Sclerosis)
CNS & Neurological Disorders - Drug Targets Potential Control of Multiple Sclerosis by Cannabis and the Endocannabinoid System
CNS & Neurological Disorders - Drug Targets Regulation of Ocular Immune Responses by Corneal Epithelium
Current Immunology Reviews (Discontinued) Protein Bioinformatics Applied to Virology
Current Protein & Peptide Science Virus Diagnostics on Microarrays
Current Pharmaceutical Biotechnology Using Non-Pharmacological Approaches for CJD Patient and Family Support as Provided by the CJD Foundation and CJD Insight
CNS & Neurological Disorders - Drug Targets Expression and Function of Cytokines and Chemokines in Neuropsychiatric Related Systemic Lupus Erythematosus
Current Rheumatology Reviews Targeting Proteasomal Pathways by Dietary Curcumin for Cancer Prevention and Treatment
Current Medicinal Chemistry Immunotherapy for Alzheimers Disease: Rational Basis in Ongoing Clinical Trials
Current Pharmaceutical Design Experimental and Clinical Application of Plasmid DNA in the Field of Central Nervous Diseases
Current Gene Therapy An Ion Channel Chip for Diagnosis and Prognosis of Autoimmune Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Editorial (Thematic Issue: Neuroglia as a Central Element of Neurological Diseases: An Underappreciated Target for Therapeutic Intervention)
Current Neuropharmacology Inflammatory Risk Factors and Pathologies Associated with Alzheimers Disease
Current Alzheimer Research Arboviral Encephalitis and RNAi Treatment
Central Nervous System Agents in Medicinal Chemistry Predicting the Potential Public Health Impact of Disease-Modifying HIV Vaccines in South Africa: The Problem of Subtypes
Current Drug Targets - Infectious Disorders